Thread by @BullsforBears

Piramal Q2 results update
28% increase in equity
39% reduction in debt D/E 0.96
12% YoY increase net profit 1124cr
No.of exposure >15% net worth of financial services - 1
Pharma arm valued EV of $ 2.7-3.1bn
CDMO revenue growth YoY 20%
@PiramalGroup #pharma #Nifty #sensex

https://twitter.com/BullsforBears/status/1275427135910490112

India consumer product YoY growth +25%
Ebidta margin Q2fy21 23%
Net debt :
Mar'19 - 55,122cr
Oct'20 - 33457 cr
D/E - 2 to 0.96
Segment wise equity allocation
Financial 48%
Pharma 22%
Unallocated 23%

Equity of 25,000 cr for financial services to acquire oppurtunities

Consolidation in real estate picking pace - industry wise decline in number of developers since 2012 - 53%

Wholesale loanbook
Mar 19 - 51436cr
Sep 20 - 45840cr

Top 10 exposure
Mar 19 - 18404cr
Sep 20 - 14717cr,down by 20%
No.of account with> 15% net worth decreased frm 3 to 1

Performance indicators financial services:
Loan book 51522 cr
Net debt 34634 cr
D/E 2.1
NIM 6.3%
C/I Ratio 17.4%
GNPA 2.5
NPA 1.6
ROA 3.8
ROE 12

Pharma
Raised $490mn fresh equity for 20% stake ,valuing it at $2775mn ,received 3523cr from carlyle on closure

Pharma delivered revenue 1441cr(+9% YoY) in Q2 ,44% of PEL overall revenue
#CDMO Inr 866cr +20% YoY
Complex hospital generics 438cr -8% YoY
India consumer products 140cr +25% YoY
Ebidta inr 327 cr with margins at 23%

4 successful regulatory inspections during Q2fy21
#pharma

Successfully closed 36 @US_FDA inspections since 2012

49% stake in Allergan india
Revenue 393 cr & net profit 104cr in FY20

CDMO - 4 new chemical entities (NCE) approval in H1
India consumer products - launched 15 products & 38 SKUs in H1 including #COVID19 masks,sanitizer